Publications

Detailed Information

The telomere maintenance mechanism spectrum and its dynamics in gliomas

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors

Kim, Sojin; Chowdhury, Tamrin; Yu, Hyeon Jong; Kahng, Jee Ye; Lee, Chae Eun; Choi, Seung Ah; Kim, Kyung-Min; Kang, Ho; Lee, Joo Ho; Lee, Soon-Tae; Won, Jae-Kyung; Kim, Kyung Hyun; Kim, Min-Sung; Lee, Ji Yeoun; Kim, Jin Wook; Kim, Yong-Hwy; Kim, Tae Min; Choi, Seung Hong; Phi, Ji Hoon; Shin, Young-Kyoung; Ku, Ja-Lok; Lee, Sungyoung; Yun, Hongseok; Lee, Hwajin; Kim, Dokyoung; Kim, Kyoungmi; Hur, Junho K.; Park, Sung-Hye; Kim, Seung-Ki; Park, Chul-Kee

Issue Date
2022-08-11
Publisher
BMC
Citation
Genome Medicine, 14(1):88
Keywords
GliomaTelomere maintenance mechanismTERTALT
Abstract
Background : The activation of the telomere maintenance mechanism (TMM) is one of the critical drivers of cancer cell immortality. In gliomas, TERT expression and TERT promoter mutation are considered to reliably indicate telomerase activation, while ATRX mutation and/or loss indicates an alternative lengthening of telomeres (ALT). However, these relationships have not been extensively validated in tumor tissues.
Methods : Telomerase repeated amplification protocol (TRAP) and C-circle assays were used to profile and characterize the TMM cross-sectionally (n = 412) and temporally (n = 133) across glioma samples. WES, RNA-seq, and NanoString analyses were performed to identify and validate the genetic characteristics of the TMM groups.
Results : We show through the direct measurement of telomerase activity and ALT in a large set of glioma samples that the TMM in glioma cannot be defined solely by the combination of telomerase activity and ALT, regardless of TERT expression, TERT promoter mutation, and ATRX loss. Moreover, we observed that a considerable proportion of gliomas lacked both telomerase activity and ALT. This telomerase activation-negative and ALT negative group exhibited evidence of slow growth potential. By analyzing a set of longitudinal samples from a separate cohort of glioma patients, we discovered that the TMM is not fixed and can change with glioma progression.
Conclusions : This study suggests that the TMM is dynamic and reflects the plasticity and oncogenicity of tumor cells. Direct measurement of telomerase enzyme activity and evidence of ALT should be considered when defining TMM. An accurate understanding of the TMM in glioma is expected to provide important information for establishing cancer management strategies.
ISSN
1756-994X
Language
English
URI
https://doi.org/10.1186/s13073-022-01095-x

https://hdl.handle.net/10371/184477
DOI
https://doi.org/10.1186/s13073-022-01095-x
Files in This Item:
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share